Can Hims & Hers Stock Recover Through a Strategic Pivot?

The telehealth company Hims & Hers is embarking on a significant strategic shift, moving its focus toward men’s hormone therapies. This new direction follows a challenging period for its once-lucrative weight-loss medication business, which had previously unsettled investors.

A New Partnership and Market Focus

In a strategic move announced earlier this week, Hims & Hers revealed an exclusive partnership with Marius Pharmaceuticals. The core of this alliance is the planned exclusive distribution of KYZATREX®, an FDA-approved oral testosterone medication, through the Hims & Hers digital platform starting in 2026.

This initiative targets a substantial market opportunity. An estimated 20 million men in the United States are affected by low testosterone levels. The company already provides access to individually dosed Enclomiphene formulations on its platform, a treatment designed to stimulate the body’s natural testosterone production.

Analyst Perspectives on the Shift

Market experts are offering mixed reactions to this strategic diversification. On Friday, Canaccord Genuity reaffirmed its “Buy” rating on the stock. The firm’s analysts highlighted the company’s strategic repositioning and its ongoing international expansion plans as key catalysts for potential growth.

Should investors sell immediately? Or is it worth buying Hims & Hers?

However, a consensus among analysts remains divided. While BTIG has also issued a buy recommendation, other major investment firms maintain “Hold” or “Underperform” ratings on the shares. The central question for all observers is whether Hims & Hers can successfully scale these new offerings rapidly enough to capture meaningful market share.

This pivot appears to be a direct response to recent headwinds, including the conclusion of its partnership with Novo Nordisk and increased regulatory scrutiny within the weight-management drug sector, prompting the search for more stable revenue streams.

The upcoming quarterly earnings reports will be critical in determining if this new strategy can meet the growth expectations now placed upon it and guide the stock toward a recovery.